Core Viewpoint - Jazz Pharmaceuticals (JAZZ) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Earnings Performance - The company has a solid track record of surpassing earnings estimates, with an average surprise of 17.04% over the last two quarters [2]. - In the last reported quarter, Jazz achieved earnings of $6.61 per share, exceeding the Zacks Consensus Estimate of $5.47 per share by 20.84%. In the previous quarter, it reported earnings of $5.30 per share against an expectation of $4.68 per share, resulting in a surprise of 13.25% [3]. Earnings Estimates and Predictions - Estimates for Jazz have been trending upward, influenced by its history of earnings surprises. The stock currently has a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of another earnings beat [4]. - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise, suggesting that out of 10 such stocks, approximately seven may exceed consensus estimates [5]. Earnings ESP and Analyst Sentiment - Jazz has an Earnings ESP of +1.27%, indicating that analysts are optimistic about its near-term earnings potential. This positive ESP, combined with a Zacks Rank of 3, suggests a possible upcoming earnings beat [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate than earlier predictions [6].

Group 1 - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) shares have experienced a significant rally following a positive 3Q24 earnings report on November 6th and subsequent FDA approval two weeks later [4] - The company operates in the neuroscience and oncology sectors, indicating a focus on high-potential therapeutic areas [4] - The current CEO of Jazz Pharmaceuticals has been highlighted, suggesting leadership stability during this growth phase [4] Group 2 - The Biotech Forum has been actively discussing profitable buy-write or covered call strategies on selected biotech stocks, indicating a strong interest in options trading within the sector [2] - The forum provides a model portfolio featuring 12-20 high upside biotech stocks, showcasing a curated investment approach [3] - Weekly market commentary and portfolio updates are offered, reflecting a commitment to ongoing analysis and investor engagement [3]

DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT. A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https:/ ...

Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the BoardMr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total RevenueBoard Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive ...

Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United StatesFor U.S. media and investors onlyDUBLIN, Dec. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A treatment ...

DUBLIN, Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT to provide an overview of clinical data, patient need and commercialization strategy for Ziihera® (zanidatamab-hrii), the first chemotherapy-free dual HER2-targeted bispecific antibody indicated for biliary tract cancer (BTC). Ziihera was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on N ...

Core Insights - Jazz Pharmaceuticals is showcasing its advancements in oncology research at two major conferences: the 2024 San Antonio Breast Cancer Symposium (SABCS) and the 66th Annual American Society of Hematology (ASH) Annual Meeting [1][3] - The company will present significant data on its drug Ziihera® (zanidatamab-hrii), which has recently received FDA approval for treating HER2-positive biliary tract cancer [3][10] - Jazz is committed to improving treatment outcomes for patients with challenging HER2-positive cancers through ongoing clinical trials [3][9] SABCS Presentations - Jazz will present a trial-in-progress poster for the Phase 3 EmpowHER303 trial, comparing zanidatamab with trastuzumab in patients with metastatic HER2-positive breast cancer [2] - A spotlight presentation will feature new data from a Phase 1b/2 study of zanidatamab combined with evorpacept in patients with pre-treated HER2-positive and HER2-low metastatic breast cancer [2] ASH Presentations - At ASH 2024, Jazz will highlight 13 abstracts focusing on oncology research, emphasizing its dedication to enhancing standards of care in blood cancers and hematologic diseases [3] - Key presentations will include a randomized comparison of Vyxeos® (daunorubicin and cytarabine) in high-risk acute myeloid leukemia patients [4][25] Ziihera® Overview - Ziihera is a bispecific HER2-directed antibody that targets two extracellular sites on HER2, leading to tumor growth inhibition and cell death [8] - The drug is indicated for adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer, with FDA approval based on overall response rates [8][10] Development and Designations - Ziihera has received Breakthrough Therapy designation for HER2 gene-amplified biliary tract cancer and Fast Track designations for other indications [10] - The drug is being developed in collaboration with BeiGene, under license from Zymeworks, and is part of a broader clinical program aimed at solid tumors expressing HER2 [9][10]

Shares of Jazz Pharmaceuticals (JAZZ) have gained 11.5% over the past four weeks to close the last trading session at $122.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $177.06 indicates a potential upside of 44.4%.The average comprises 18 short-term price targets ranging from a low of $120 to a high of $230, with a standard deviation of $31.55. While the lowest estimate i ...

Jazz Pharmaceuticals (JAZZ) announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will be marketed under the trade name Ziihera.With this nod, Ziihera gets approved for use in previously treated adult patients with unresectable or metastatic HER2-positive BTC. The approval also makes this drug the first dual HER2-targeted bispecific antibody and chemotherapy-free therapy for treating BTC in th ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-an ...